Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 7, 2007
New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype allelesSatoko Matsueda, Hiroko Takedatsu, Tetsuro Sasada, et al.
International Journal of Oncology|October 8, 2005
Identification of human papillomavirus 16-E6 protein-derived peptides with the potential to generate cytotoxic T-lymphocytes toward human leukocyte antigen-A24+ cervical cancerMiho Hara, Satoko Matsueda, Mayumi Tamura, et al.
International Journal of Oncology|March 3, 2007
Novel natural immunogenic peptides from Numb1 and Notch1 proteins for CD8+ cells in ovarian ascitesSatoshi Ishiyama, Satoko Matsueda, Lovell A Jones, et al.
The Prostate|September 25, 2004
New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patientsAkihisa Yao, Mamoru Harada, Satoko Matsueda, et al.
Oncoimmunology|May 10, 2019
Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancerMuzamil Yaqub Want, Anna Konstorum, Ruea-Yea Huang, et al.
Cancer Science|August 14, 2014
PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancerKayoko Waki, Teppei Yamada, Koichi Yoshiyama, et al.
Oncology Reports|June 21, 2013
A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patientsShigeru Yutani, Nobukazu Komatsu, Munehiro Yoshitomi, et al.
Cancer Immunology, Immunotherapy : CII|December 3, 2008
Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cellsTakashi Mine, Satoko Matsueda, Yufeng Li, et al.
Virology Journal|September 18, 2012
Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptidesAkimasa Fukui, Satoko Matsueda, Kouichiro Kawano, et al.
Immunopharmacology and Immunotoxicology|April 30, 2014
Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patientsKouichiro Kawano, Naotake Tsuda, Satoko Matsueda, et al.
Pageof 9